Inhaled nitric oxide for high-altitude pulmonary edema

The New England Journal of Medicine
U ScherrerPeter Bärtsch

Abstract

Pulmonary hypertension is a hallmark of high-altitude pulmonary edema and may contribute to its pathogenesis. When administered by inhalation, nitric oxide, an endothelium-derived relaxing factor, attenuates the pulmonary vasoconstriction produced by short-term hypoxia. We studied the effects of inhaled nitric oxide on pulmonary-artery pressure and arterial oxygenation in 18 mountaineers prone to high-altitude pulmonary edema and 18 mountaineers resistant to this condition in a high altitude laboratory (altitude, 4559 m). We also obtained lung-perfusion scans before and during nitric oxide inhalation to gain further insight into the mechanism of action of nitric oxide. In the high-altitude laboratory, subjects prone to high-altitude pulmonary edema had more pronounced pulmonary hypertension and hypoxemia than subjects resistant to high-altitude pulmonary edema. Arterial oxygen saturation was inversely related to the severity of pulmonary hypertension (r=-0.50, P=0.002). In subjects prone to high-altitude pulmonary edema, the inhalation of nitric oxide (40 ppm for 15 minutes) produced a decrease in mean (+/-SD) systolic pulmonary-artery pressure that was three times larger than the decrease in subjects resistant to such edema (2...Continue Reading

References

Sep 26, 1992·Lancet·J B West, O Mathieu-Costello
Oct 1, 1992·International Journal of Sports Medicine·P H HackettB D Levine
Oct 31, 1991·The New England Journal of Medicine·P BärtschO Oelz
May 30, 1991·The New England Journal of Medicine·A T Dinh-XuanJ Wallwork
Nov 25, 1989·Lancet·O OelzP Bärtsch
Jun 1, 1988·Journal of Applied Physiology·R B SchoeneT R Martin
May 8, 1980·The New England Journal of Medicine·N C Staub
Dec 1, 1994·Circulation·W J ManningP S Douglas
Jan 1, 1963·British Medical Bulletin·J B WEST
Mar 1, 1964·Circulation·H N HULTGRENH MILLER
Sep 8, 1960·The New England Journal of Medicine·C S HOUSTON

❮ Previous
Next ❯

Citations

Nov 19, 2009·Journal of Anesthesia·Kay B Leissner, Feroze U Mahmood
Feb 6, 2004·Pharmacology & Therapeutics·Heather MortimerAndrew J Peacock
Jun 13, 2003·Lancet·Buddha Basnyat, David R Murdoch
Feb 1, 1997·Emergency Medicine Clinics of North America·K Zafren, B Honigman
Mar 25, 2000·Journal of the American College of Cardiology·E GrünigP Bärtsch
Mar 7, 1996·The New England Journal of Medicine·E H Jerome, J W Severinghaus
Jul 14, 2001·The New England Journal of Medicine·P H Hackett, R C Roach
Oct 30, 2001·The New England Journal of Medicine·R I Ogilvie
Oct 24, 2002·The New England Journal of Medicine·Nicholas L M CrudenDavid J Webb
May 25, 2002·The New England Journal of Medicine·Claudio SartoriUrs Scherrer
Jan 9, 2009·The New England Journal of Medicine·Michael P W GrocottUNKNOWN Caudwell Xtreme Everest Research Group
Dec 24, 2005·The New England Journal of Medicine·Mark J D Griffiths, Timothy W Evans
May 22, 2007·Antioxidants & Redox Signaling·Ioana R Preston
Apr 12, 2003·Critical Care Medicine·Udo KaisersKonrad J Falke
Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·J W ZieglerS H Abman
Feb 17, 2001·American Journal of Respiratory and Critical Care Medicine·T BuschE R Swenson
Nov 2, 2004·American Journal of Respiratory and Critical Care Medicine·Jean-Paul RichaletJérémy Cornolo
Jun 11, 2005·American Journal of Respiratory and Critical Care Medicine·Marc M BergerWalter E Haefeli
Sep 2, 2006·American Journal of Respiratory and Critical Care Medicine·Christoph DehnertChristian Fink
Nov 11, 2006·American Journal of Respiratory and Critical Care Medicine·Luc J TeppemaMarc J Poulin
Sep 9, 2008·American Journal of Respiratory Cell and Molecular Biology·Shelley X L ZhangYang Wang
Dec 23, 2008·Wilderness & Environmental Medicine·Joshua O Stream, Colin K Grissom
Oct 30, 2001·High Altitude Medicine & Biology·R B Schoene
Oct 17, 2003·High Altitude Medicine & Biology·Johanna WeissPeter Bärtsch
Jul 22, 2004·High Altitude Medicine & Biology·Robert B Schoene
Mar 18, 2005·High Altitude Medicine & Biology·Antoni RicartGinés Viscor
Sep 19, 2006·High Altitude Medicine & Biology·Tianyi Wu, Bengt Kayser
Jun 27, 2008·High Altitude Medicine & Biology·Andrew M Luks
Sep 20, 2008·High Altitude Medicine & Biology·Ralf GeigerAlexander Loeckinger
Jan 1, 2009·High Altitude Medicine & Biology·Marcos SchwabUrs Scherrer
Jul 2, 2011·High Altitude Medicine & Biology·Andrew M Luks, Erik R Swenson
Jun 26, 2013·High Altitude Medicine & Biology·Urs ScherrerClaudio Sartori
May 6, 2010·The American Journal of the Medical Sciences·Biff F Palmer
Apr 4, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chia-Ti WangChing-Ping Chang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.